Thibault Comont, MD
@thibault_comont
Associate Professor in Immuno- hematology department, IUCT Oncopole, CHU de Toulouse, France @jeansarry #mds #mdssm #vexas #itp #cerecai #gfm
Adoptive natural killer (NK) cell therapy may have a role to play in clonal cytopenia of unknown significance (CCUS) and could help prevent CCUS patients from developing myelodysplastic syndrome (#MDS) & #AML #leukemia NK immune cells derived from pre-leukemic bone marrow stem…
doi.org/10.1002/ajh.27… Durable Responses with Front-line Rituximab in Autoimmune Cytopenias associated with indolent B-cell clones Now online in @AjHematology Well done Yoann Zadro
📢 New multicentre real‑life study by the GFM now published in British Journal of Haematology! 🩸 #mds #mdsm #gfm British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…
Join us for a 2-hour post #ASCO25 & #EHA25 @vjhemonc updates in #MDSsm of the most important abstracts delivered in abbreviated format by the authors themselves & then discussed by panels of experts. Register at Post-EHA 2025 MDS Highlights | VJHemOnc vjhemonc.com/event/post-eha…
It’s online ! Happy to share with you: Incidence and burden of lower-risk myelodysplastic syndrome: a nationwide population study - Clinical Lymphoma, Myeloma and Leukemia clinical-lymphoma-myeloma-leukemia.com/article/S2152-…
Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. news.abbvie.com/2025-06-16-Abb…
It was an honor to present on behalf the Frenvex our results on Aza in #VEXAS syndrome at #EHA2025
🔥 POS1124 | A major step for #VEXAS: an international expert panel reached consensus on the definition of a VEXAS flare using Delphi methodology. ➡️3 categories, adjudication pathway, and a clear criterion: GC escalation. Crucial for trials, therapy, and patient care. #EULAR2025
To be cited in #EHA2025 by #mdsm experts ! Proud #VEXAS
Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade: Cell Reports Medicine cell.com/cell-reports-m…
NEW RESEARCH—A retrospective cohort study from the UK reports treatment outcomes of targeted therapies in patients with #VEXAS syndrome thelancet.com/journals/lanrh… @TYoungstein @jamesapoulter
Excited to share with all our latest work on the use of single cell tools in following IDH mutant AML patients during their treatment! Out today @CellStemCell !! An amazing collaboration with @AkEisfeld & @PapaemmanuilLab & @landau_lab !!! Driven by the impressive @MariaSirenko…
Excited to share our @nih_nhlbi group’s latest work, led by post-doc Hiroki Mizumaki, looking at the role of the adaptive and innate immune system in #VEXAS in @NatureComms. nature.com/articles/s4146… @bhavishap29 @fergutierrezro1 @NealSYoung1
Catch up on the latest breakthroughs in #HemOnc with our expert-led Post-#EHA2025 Highlights webinars 📣💻📍@EHA_Hematology The #MDS session will be chaired by @Dr_AmerZeidan & moderated by Dr Lisa Pleyer & @beatalleukemia 🔗 REGISTER 👉 us06web.zoom.us/webinar/regist…
Congratulations to Dr. Rivet for carrying out and publishing this very interesting work on acral vasculitis induced by checkpoint inhibitors. And thank you to all our colleagues at IUCT-Oncopole frontiersin.org/journals/oncol…
Analyses of single-cell transcriptomic data from patients with VEXAS syndrome combined with xenotransplant experiments in a mouse model of the disease provide insights on the mechanisms of clonal dominance of mutated cells leading to bone marrow failure. nature.com/articles/s4159…
Excited to present the results of our study on the efficacy of azacitidine in VEXAS syndrome today at the SFH Congress! #VEXAS #Azacitidine #SFH
